Browsing Tag
MetaVia Inc.
3 posts
Why MetaVia’s patent move may matter more than early weight loss data in the obesity market
MetaVia Inc. secures patent protection for its dual incretin obesity drug DA-1726 through 2041. Find out why this matters for investors and competitors.
MetaVia (NASDAQ: MTVA) raises $9.3m to advance DA-1726 after positive Phase 1b obesity data
MetaVia raised $9.3M to fund DA-1726 after strong obesity trial results. Find out how this dual-agonist strategy could reshape the GLP-1 landscape.
MetaVia unveils breakthrough Phase 2a data showing vanoglipel improves liver markers and glucose control in MASH patients
Find out how MetaVia’s vanoglipel improved liver enzymes and glucose control in its Phase 2a MASH trial — see why investors are taking notice today.